

Maria Efthymiou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2252687/publications.pdf>

Version: 2024-02-01

22
papers

907
citations

758635

12
h-index

676716

22
g-index

22
all docs

22
docs citations

22
times ranked

1319
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. <i>Lancet Haematology</i> , 2016, 3, e426-e436.	2.2	322
2	Mutations in BMP4 Cause Eye, Brain, and Digit Developmental Anomalies: Overlap between the BMP4 and Hedgehog Signaling Pathways. <i>American Journal of Human Genetics</i> , 2008, 82, 304-319.	2.6	221
3	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 464-468.	1.6	79
4	Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2022, 74, 324-335.	1.5	39
5	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019, 71, 134-141.	1.5	37
6	Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome. <i>Thrombosis Research</i> , 2015, 135, 1191-1197.	0.8	31
7	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020, 29, 1353-1363.	0.8	28
8	Monitoring of anticoagulation in thrombotic antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 892-908.	1.9	20
9	Under crossfire: thromboembolic risk in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 940-952.	0.9	19
10	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021, 48, 541-547.	1.0	19
11	Direct Oral Anticoagulants for Thromboprophylaxis in Patients with Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 427-438.	1.5	13
12	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019, 175, 32-36.	0.8	13
13	Protective Effects of Non-Anticoagulant Activated Protein C Variant (D36A/L38D/A39V) in a Murine Model of Ischaemic Stroke. <i>PLoS ONE</i> , 2015, 10, e0122410.	1.1	12
14	Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?. <i>Rheumatology</i> , 2021, 60, 1376-1386.	0.9	11
15	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2069-2080.	1.9	9
16	Antibodies against TFPI and protein C are associated with a severe thrombotic phenotype in patients with and without antiphospholipid syndrome. <i>Thrombosis Research</i> , 2018, 170, 60-68.	0.8	7
17	Management of anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Lancet Haematology</i> , 2020, 7, e613-e623.	2.2	6
18	Comparative sensitivity of commonly used thromboplastins to ex vivo therapeutic rivaroxaban levels. <i>Thrombosis and Haemostasis</i> , 2014, 112, 421-423.	1.8	5

#	ARTICLE	IF	CITATIONS
19	Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment. <i>Current Rheumatology Reports</i> , 2017, 19, 50.	2.1	5
20	Use of direct oral anticoagulants in antiphospholipid syndrome: Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 259-261.	1.9	5
21	Rivaroxaban Limits Complement Activation Compared to Warfarin in Antiphospholipid Syndrome Patients with Venous Thromboembolism. <i>Blood</i> , 2015, 126, 2328-2328.	0.6	3
22	Comparison of Acquired Activated Protein C Resistance, Using the CAT and ST-Genesia® Analysers and Three Thrombin Generation Methods, in APS and SLE Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 69.	1.0	3